ReGen Biologics Inc. (PINK:RGBO) doesn’t have enough money to pay for its annual earnings filing with the Securities & Exchange Commission.
Q4
Derma Sciences sales jump 16 percent | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Syneron sees 250 percent jump in sales in 2010 | Earnings roundup
Syneron Medical Ltd. (NSDQ:ELOS) reported a 250 percent increase in sales during 2010, as the aesthetic device maker began to see some payoff from its 2009 acquisition of Candela Corp.
Syneron, a Yokneam, Israel aesthetic device company reported $189 million in sales during the year ending on Dec. 31, 2010, compared to $54 million for the same period last year. Much of that increase is directly attributed to products the company picked up in its $65 million acquisition of Candela Corp. in Sept. 2009.
Invivo Therapeutics reports $9 million net loss in 2010
InVivo Therapeutics Holdings Corp. (OTC:NVIV), which raised close to $12 million when it went public last year, reported a $9 million net loss for the year ending Dec. 31.
The Cambridge, Mass.-based startup, which is developing an implantable treatment of acute spinal chord injuries, said the 260 percent increase in net losses was attributable to “a non-cash charge of $5,099,000 for derivative losses.” Since its inception in 2005, Invivo has lost more than $14.2 million.
Smiths’ H1 sales rise 7 percent | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Alcon profits, revenues jump 10 percent | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Sluggish stent sales at Boston Scientific continue to afflict Angiotech
The best thing you can say about Angiotech Pharmaceutical Inc.’s (NSDQ:ANPI) fourth quarter is that it’s over.
Dehaier profits are 70 percent higher | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Kendle stock tumbles 15 percent on Q4 losses
Contract research organization Kendle International Inc. (NSDQ:KNDL) saw its stock plummet 15 percent a day after it announced a $9 million fourth-quarter loss.
Kendle’s stock closed at $10.28 after the Cincinnati-based CRO reported its fourth-quarter and full-year earnings after market close the prior day.
Kendle lost $9 million, or 62 cents per share, in the fourth quarter compared with net income of $2 million, or 16 cents per share, in the fourth quarter of 2009.
Kendle’s Q4 drags 2010 into the red | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Fourth-quarter profits not enough for some Psychemedics investors
Psychemedics Corp. (NYSE:PMD) shares are down about 2 percent, paring earlier losses after the drug-testing firm turning in smaller fourth-quarter profits despite a 19.7 percent jump in Q4 revenues.